Track topics on Twitter Track topics that are important to you
There were more deaths in patients taking Johnson and Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.
Reuters Health Information
Original Article: J&J Arthritis Drug Sirukumab Raises Safety Concerns -FDA StaffNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...